FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap
The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.